quinuclidines has been researched along with Carcinoma, Ovarian Epithelial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arsiola, T; Böckelman, C; Butt, U; Butzow, R; Carpen, O; Connolly, DC; Cvrljevic, AN; Grönroos, TJ; Haglund, C; Huhtinen, K; Kaipio, K; Laajala, TD; Lassus, H; Pouwels, J; Ristimäki, A; Westermarck, J | 1 |
| Callen, D; Kajiyama, H; Kikkawa, F; Mitsui, H; Nakamura, K; Niimi, K; Sekiya, R; Shibata, K; Suzuki, S; Utsumi, F; Yoshikawa, N | 1 |
2 other study(ies) available for quinuclidines and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype.
Topics: Animals; Autoantigens; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Mice; NF-kappa B; Ovarian Neoplasms; Quinuclidines | 2022 |
PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Proteolysis; Quinuclidines; Reactive Oxygen Species; Tumor Suppressor Protein p53 | 2016 |